Free Submission Public Relations & NewsPR-inside.com
 
DeutschEnglish

Get the latest news
with our RSS feed
rss feed
Add to My Yahoo!
More information
Business

Gilead Sciences to Present at the Thomas Weisel Partners Healthcare Conference on Wednesday, September 3


Print article Print article
Refer this article Refer to a friend
© Business Wire 2008
2008-08-28 00:20:01 -

www.gilead.com - Gilead Sciences, Inc. Patrick O'Brien, Investor Relations, 650-522-1936 Gilead Sciences, Inc. (Nasdaq:GILD) today announced that its corporate presentation will be webcast from the Thomas Weisel Partners Healthcare Conference in Boston.

John C. Martin, PhD, Gilead's Chairman and Chief Executive Officer, will provide an overview of the company on Wednesday, September 3 at 10:55 a.m. Eastern Time.

To access the live webcast via the internet log on to www.gilead.com. Please connect to the company's website at least 15 minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary to listen to the webcast.

About Gilead

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

For more information on Gilead Sciences, please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).

Webcast Available Through Gilead Corporate Website


Disclaimer: (c) 2009 Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Terms & Conditions | Privacy | About us | Contact PR-inside.com